Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0395 • ACR Convergence 2022
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Juergens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Christina Budden⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁴Medizinische Hochschule Hannover, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: There is a higher prevalence of obesity in patients (pts) with psoriatic disease1. The German non-interventional study AQUILA provides real-world data on the influence…
Abstract Number: 1004 • ACR Convergence 2022
SPARCC, MASES, LEI and MEI Indexes Capture Different Patients with Enthesitis in Axial Spondyloarthritis, Peripheral Spondyloartrhitis and Psoriatic Arthritis
Raquel Granados¹, lourdes Ladehesa-Pineda², Maria Angeles Puche Larrubia³, Maxime Dougados⁴, Eduardo Collantes⁵ and Clementina Lopez-Medina⁶, ¹Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ²Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ³Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, ⁴Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ⁶Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain
Background/Purpose: Spondyloarthritis, (axial (axSpA), peripheral (pSpA)) and psoriatic arthritis (PsA)) share enthesitis as a hallmark clinical feature. Reliable clinical instruments have been developed to assess…
Abstract Number: 1036 • ACR Convergence 2022
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by History of Cigarette Smoking
Alexis Ogdie¹, Lars Erik Kristensen², Enrique R Soriano³, Servet Akar⁴, Yanhui Sun⁵, David Gruben⁶, Lara Fallon⁷, Cassandra D Kinch⁸ and Dafna Gladman⁹, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²The Parker Institute, Copenhagen University Hospital, Copenhagen, Denmark, ³Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁵Pfizer CRDC, Shanghai, China, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Montréal, QC, Canada, ⁸Pfizer Canada ULC, Kirkland, Canada, ⁹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: In patients (pts) with PsA and AS, smoking may be associated with an increased comorbidity burden, and greater responses to TNF inhibitors (TNFi) are…
Abstract Number: 1209 • ACR Convergence 2022
Impact of Change in Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of Psoriatic Arthritis Patients
Zhaohui Su¹, Lauren Stevens², Tom Brecht¹, Jessica Paulus¹ and Stefan Weiss³, ¹OM1, Inc., Boston, MA, ²OM1, Inc., Lexington, KY, ³OM1, Inc., Chapel Hill, NC
Background/Purpose: While many clinical trials provide direct comparisons between biologic disease modifying antirheumatic drugs (bDMARD) and nonbiologic DMARDs (nDMARD), there is a need for to…
Abstract Number: 1493 • ACR Convergence 2022
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry
Philip J Mease¹, Miroslawa Nowak², Jiyoon Choi³, Tom Lehman², Antoine Sreih⁴, Taylor Blachley⁵, Blessing Dube⁵, Kaylee Ho⁵, Nicole Middaugh⁵ and Alexis Ogdie⁶, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Bristol Myers Squibb, Princeton, NJ, ³Bristol Myers Squibb, Lawrenceville, NJ, ⁴Bristol Myers Squibb, Philadelphia, PA, ⁵CorEvitas, LLC, Waltham, MA, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is evidence that a delay between psoriatic arthritis (PsA) symptom onset and diagnosis contributes to worse outcomes, yet the impact of delayed DMARD…
Abstract Number: 1600 • ACR Convergence 2022
The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Robert McLean², Taylor Blachley², Nicole Middaugh², Manish Mittal³, Jerry Clewell³, Sandra Ciecinski⁴ and Philip J Mease⁵, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³AbbVie, Inc., North Chicago, IL, ⁴AbbVie, Inc., Mettawa, IL, ⁵Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: While evidence in patients (pts) with RA suggests that switching to a therapy with a different mechanism of action (MOA) may be more effective…
Abstract Number: 2111 • ACR Convergence 2022
Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Dafna Gladman¹, Michael Starr², Roberto Ranza³, Ana-Maria Bravo Perdomo⁴, Marcie Strauss⁵, May Shawi⁶, Chenglong Han⁷, Emmanouil Rampakakis⁸, Andrew Ostor⁹ and Philip J Mease¹⁰, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Montreal General Hospital, Montréal, QC, Canada, ³Serviço de Reumatología, Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁴Immunology Medical Affairs, Janssen Latin America, Columbia, Colombia, ⁵Medasource, Indianapolis, IN, ⁶Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁷Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹Cabrini Medical Centre, Monash University & Emeritus Research, Melbourne, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: The IL-23p19-subunit inhibitor guselkumab (GUS) demonstrated clinically meaningful improvements in fatigue through one year of treatment1 independent of its effects on ACR20 and MDA…
Abstract Number: 2127 • ACR Convergence 2022
Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years
Laura Coates¹, Laure Gossec², Christine Contré³, May Shawi⁴, Emmanouil Rampakakis⁵, Natalie Shiff⁶, Alexa Kollmeier⁷, Xie L Xu⁸, Peter Nash⁹, Philip J Mease¹⁰ and Philip Helliwell¹¹, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ²Sorbonne Université, Paris, France, ³Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ⁴Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁵McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, ⁷Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁸Janssen Research & Development, LLC, San Diego, CA, USA, San Marcos, CA, ⁹School of Medicine, Griffith University, Sunshine Coast, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Recent guidelines from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommend that psoriatic arthritis (PsA) therapy achieve lowest possible…
Abstract Number: 2144 • ACR Convergence 2022
JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis
Maria Gabriella Raimondo¹, Charles Gwellem Anchang¹, Hannah Labinsky², Mina Saad Aziz Saad¹, Simon Rauber¹, Mario Vogg¹, Eleni Kampylafka¹, Johannes Knitza¹, Alina Soare¹, Georg Schett³ and Andreas Ramming¹, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Janus Kinase (JAK)/Signal Transducers and Activator of Transcription (STAT) is not only involved in IL23- signaling, but rather implemented into a broad range of…
Abstract Number: 0189 • ACR Convergence 2022
Characteristics Associated with a Positive PEST Screening Among Patients with Psoriasis Without a Diagnosis of Psoriatic Arthritis: Results from the Global Psoriasis and Beyond Study
Alexis Ogdie¹, April Armstrong², Barbra Bohannan³, Sicily Mburu⁴, Laura Coates⁵, Elena Kornyeyeva⁶, Susan Frade⁶, Silvia Fernandez Barrio⁷ and Matthias Augustin⁸, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Keck School of Medicine of USC, Dermatology, Los Angeles, CA, ³Psoriasisförbundet, Stockholm, Sweden, ⁴IFPA, Stockholm, Sweden, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Asociación Para El Enfermo De Psoriasis, Buenos Aires, Argentina, ⁸University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Background/Purpose: Psoriatic arthritis (PsA) is a common clinical feature in patients (pts) with psoriasis (PsO); up to one third of PsO pts will develop PsA…
Abstract Number: 0400 • ACR Convergence 2022
Is There Any Influence of Gender on the Sociodemographic and Clinical Characteristics of Psoriatic Arthrithis?
Brian Manases roldan¹, Carolina A Isnardi², Virginia Carrizo Abarza¹, Maria Agustina Alfaro¹, Tatiana Barbich², Maria Gisela Crespo Rocha², Marina Fornaro², Osvaldo Luis Cerda², Fernando Dal pra², Emilce Edith Schneeberger² and Gustavo Citera², ¹Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina
Background/Purpose: To evaluate the differences in sociodemographic and clinical characteristics, disease activity, functional status and quality of life between male and female patients with PsA.Methods:…
Abstract Number: 1006 • ACR Convergence 2022
Impact of Uric Acid Levels on Clinical and Radiographic Characteristics in Psoriatic Arthritis and Response to Secukinumab: A Pooled “Post Hoc” Analysis from Five Phase 3 Studies
Renaud FELTEN¹, Laura Widawski², Lionel Spielmann², Corine Gaillez³, Weibin Bao⁴, Hugh O’Neill⁵, jacques-eric gottenberg⁶, Pierre-Marie Duret² and Laurent Messer⁷, ¹Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Colmar Civilian Hospitals, Colmar, France, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Ireland Limited, Dublin, Ireland, ⁶Strasbourg University Hospital, Strasbourg, France, ⁷Colmar Civil Hospitals, Colmar, France
Background/Purpose: Hyperuricemia (HU), a common metabolic abnormality, may result in development of gout, which is an inflammatory arthritic condition1,2. Patients (pts) with psoriasis (PsO)/psoriatic arthritis…
Abstract Number: 1037 • ACR Convergence 2022
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies
Xenofon Baraliakos¹, Dafna Gladman², Soumya Chakravarty³, Cinty Gong⁴, May Shawi⁵, Emmanouil Rampakakis⁶, Kishimoto Mitsumasa⁷, Enrique R Soriano⁸ and Philip J Mease⁹, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Although the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to assess the activity of axial disease in patients (pts) with PsA, only…
Abstract Number: 1218 • ACR Convergence 2022
Prevalence and Impact of Widespread Pain and Fibromyalgia on Measurement of Disease Severity in Psoriatic Arthritis: Lessons from the CorEvitas Registry
Philip J Mease¹, Alexis Ogdie², Dimitrios Pappas³, George Reed⁴ and Joel Kremer⁵, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³CorEvitas, LLC, Waltham, MA, ⁴The Corrona Research Foundation and University of Massachusetts, Albany, NY, ⁵The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Fibromyalgia (FM) occurs concomitantly with inflammatory rheumatic disease, including psoriatic arthritis (PsA), in up to 20% of patients and chronic widespread pain (CWP) in…
Abstract Number: 1496 • ACR Convergence 2022
Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met?
Sarah Yazji¹, Philip Helliwell², Andra Balanescu³, JUAN CANETE⁴, Emmanuelle Dernis⁵, Uta Kiltz⁶, Ying Ying Leung⁷, Ennio Lubrano⁸, Ana-Maria Orbai⁹, PENELOPE PALOMINOS¹⁰, Rossana Scrivo¹¹, Josef Smolen¹², Sandra Meisalu¹³, Maarten de Wit¹⁴, Laure Gossec¹⁵ and Laura Coates¹⁶, ¹University of Oxford, Oxford, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, ⁴Rheumatology Department, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁵LE MANS general hospital, LE MANS, France, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Rheumatology Department, Singapore General Hospital, Singapore, Singapore, ⁸Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, ⁹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁰Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ¹¹Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy, Roma, Rome, Italy, ¹²Medical University of Vienna, Vienna, Austria, ¹³East Tallinn Central Hospital, Tallinn, Estonia, ¹⁴Patient research partner, Amsterdam, Netherlands, ¹⁵Sorbonne Université, Paris, France, ¹⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: The Minimal Disease Activity (MDA) criteria evaluate PsA disease activity and response to treatment and are defined as meeting ≥5 criteria: tender joint count…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].